Respiratory Motion Artifact Affecting Hepatic Arterial Phase MR Imaging with Gadoxetate Disodium Is More Common in Patients with a Prior Episode of Arterial Phase Motion Associated with Gadoxetate Disodium

Purpose: To determine, in a dual-center setting, whether patients who experience transient severe motion (TSM) in the arterial phase during gadoxetate disodium-enhanced magnetic resonance (MR) imaging are at higher risk for a subsequent episode of TSM than patients who do not have TSM during initial gadoxetate disodium administration. Materials and Methods: Institutional review board approval was obtained for this retrospective, multi-institutional HIPAA-compliant study. The requirement for informed consent was waived. One hundred seventy patients each underwent two MR imaging examinations with bolus injection of gadoxetate disodium at one of two sites. Three radiologists reviewed the examinations at each site for TSM, based on severe arterial phase motion, despite minimal motion in the other dynamic phases. The occurrence rate of TSM in the second examination was compared between patients who had TSM in their first examination and those who did not by using the x(2) or Fisher exact test, as appropriate. Relative risks and 95% confidence intervals (CIs) were calculated. Results: TSM rates in second examinations were significantly higher for patients who had TSM in their first examination: site 1, 67% (six of nine) vs 4% (three of 69) (P < .0001); site 2, 60% (three of five) vs 6% (five of 87) (P < .005); and both sites, 64% (nine of 14) vs 5% (eight of 156) (P < .0001). Relative risks were 15 for site 1 (95% CI: 5, 51), 10 for site 2 (95% CI: 3, 32), and 13 for both sites (95% CI: 6, 27). Conclusion: Patients who experience TSM during gadoxetate disodium-enhanced MR imaging are at significantly and substantially higher risk for TSM in the next gadoxetate disodium-enhanced examination compared with patients who do not have TSM during their initial gadoxetate disodium administration. (C) RSNA, 2014